Over 150 Total Lots Up For Auction at One Location - MO 06/05

Adel Abdullah and Aaron Hargrave

Positron appoints president and vice president
October 12, 2018
Molecular Imaging PET
NIAGARA FALLS, N.Y., Sept. 27, 2018 /PRNewswire/ -- Positron Corporation (OTC :POSC )(the "Company"), a nuclear medicine healthcare company, announces the appointment of Adel Abdullah as its President. Mr. Abdullah will also serve as a Director of the Board. Mr. Abdullah will lead the Company in its strategic plan and long term objectives moving forward. Adel Abdullah has been instrumental to Positron's ability to deliver world class PET imaging technology, clinical & technical services to customers for over 10 years and will continue to do so for Positron's customers.

Positron is also pleased to announce the appointment of Aaron Hargrave, Positron's Director of Clinical Applications as Vice President. Mr. Hargrave is a Certified Nuclear Medicine Technologist, performing PET imaging in cardiac, oncology and neurologic subsets for Positron since 2010. Mr. Hargrave provides clinical and software support and training for Positron's Attrius PET customers specializing in image quality and interpreting technical data, ensuring proper product use for optimal patient outcomes.

Mr. Abdullah and Mr. Hargrave have delivered top performing PET technology used in over 50,000 cardiac studies on Positron imaging systems.
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.

stats
Mr. Abdullah stated, "It is an exciting time at Positron. As a company we are on a new path that I expect will have great impact in the growth of the cardiac PET industry. Positron is stronger than ever with the ability to focus exclusively on its imaging technology, clinical services and innovative pro-business structures for its customers. Our goal is to work with champions of the cardiac PET industry to advance the adoption of cardiac PET utilizing Positron's PET imaging systems and services."


About Positron:
Positron Corporation is a nuclear medicine healthcare company providing innovative PET technologies and practice solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron has made continues their strong commitment to excellence and advancing cardiac imaging solutions. Positron's unique products, market position and approach in facilitating the adoption of cardiac PET to customers are substantial advantages to the growth of nuclear cardiology and Positron. Positron is redefining the industry.


SOURCE Positron Corporation

You Must Be Logged In To Post A Comment

advertisement

 

advertisement

Molecular Imaging Homepage

IBA launches cyclotron for industrial-scale astatine-211 production
Cyclone iKure was developed to address production infrastructure limitations
GE HealthCare submits MIM KineticID for FDA review to support dynamic PET imaging
Dynamic PET tracks tracer behavior in blood and tissue over a longer period
Unlocking the Power of Theranostics with VERITON-CT: A New Era in Precision Medicine
Engineered with advanced digital technology and a patient-centered design, VERITON-CT offers a quantum leap in performance, accuracy, and efficiency.
Niowave breaks ground on $75 million facility to expand Actinium-225 production
New site will serve as its second dedicated production facility in Lansing, Michigan
The annual SNMMI meeting is right around the corner
Q&A with Heather Jacene, incoming SNMMI president
New radiotracers reshape access to neuroendocrine tumor imaging
Rollout of Gallium-68 DOTATATE and DOTATOC coincided with increased travel distances for patients
PharmaLogic opens PET radiopharmaceutical facility in Atlanta
Part of company's $250 million investment in U.S. radiopharma infrastructure
Clarity expands manufacturing network with Nucleus agreement for Cu-64 PSMA agent
Intended to support distribution across the US international markets of investigational prostate cancer imaging agent
SHINE gets $263 million conditional loan from DoE for Wisconsin Mo-99 facility
Intends to use a combination of fusion and fission processes to manufacture the isotope domestically
Siemens Healthineers and Radiopharm ink supply deal for RAD101 PET agent ahead of Phase 3 trial
Designed to help detect suspected recurrent brain metastases from solid tumors